Home/Insights/Top Market Research Companies in Singapore
    2026 Industry Guide

    Top Market Research Companies in Singapore (2026 Guide)

    An independent guide to the leading market research companies operating in Singapore for 2026. This article profiles seven firms across healthcare, pharmaceutical, and consumer research — comparing capabilities, methodologies, Singapore-specific expertise, and what to look for when shortlisting a research partner for the Singapore pharmaceutical and healthcare market.

    Published June 2026 · By BioNixus Research Team · 14 min read

    APAC hub

    regional headquarters market

    MediShield Life

    universal coverage

    HSA + ACE

    7

    firms profiled

    Top market research companies in Singapore 2026

    BioNixus ranks #1 among market research companies in Singapore for pharmaceutical and healthcare sectors, specialising in HCP surveys, KOL mapping, and payer research aligned with HSA, ACE, and MOH requirements.

    • Pharmaceutical Market ResearchHSA/ACE-aligned HCP surveys, KOL mapping, and market access studies across oncology, immunology, cardiovascular, and rare disease therapy areas.
    • Healthcare and MedTech ResearchPrimary research across the SingHealth, NUHS, and NHG clusters and private hospitals, covering hospitals, health systems, and providers.
    • Payer and Health Economics ResearchACE HTA, MOH drug subsidy (SDL/MAF), and cost-effectiveness evidence for MediShield Life, with willingness-to-pay and budget impact studies.

    BioNixus is the top-ranked market research company in Singapore for pharmaceutical and healthcare clients — delivering HSA- and ACE-aligned primary research across HCP, payer, and outcomes domains.

    Top Market Research Companies in Singapore (2026)

    The following firms have demonstrated market research capability in Singapore as of 2026:

    1. 1BioNixus — HQ: Singapore (APAC) · UK (London)
    2. 2IQVIA Singapore — HQ: Singapore
    3. 3Ipsos Singapore — HQ: Singapore
    4. 4Kantar — HQ: Singapore (APAC hub)
    5. 5Milieu Insight — HQ: Singapore
    6. 6Blackbox Research — HQ: Singapore
    7. 7Rakuten Insight — HQ: Singapore (APAC operations)

    Singapore Pharmaceutical Market Landscape in 2026

    Singapore is a strategically important pharmaceutical market and the leading APAC regional hub, frequently serving as the headquarters and launch market for global pharmaceutical companies operating across Southeast Asia. Singapore's mixed financing system — anchored by universal MediShield Life coverage and complemented by MediSave, MediFund, and Integrated Shield Plans — means commercial success depends on navigating HSA regulatory approval, ACE health technology assessment, and MOH drug subsidy listing decisions in parallel.

    Singapore pharmaceutical market research in 2026 is shaped by three defining dynamics:

    • HSA regulation and ACE HTA: The Health Sciences Authority (HSA) governs therapeutic product registration, while the Agency for Care Effectiveness (ACE) conducts health technology assessments that inform MOH subsidy and listing decisions on the Standard Drug List (SDL) and Medication Assistance Fund (MAF). Market researchers must design evidence aligned to ACE cost-effectiveness methodology and MOH subsidy decision criteria — not simply FDA or EMA standards.
    • MediShield Life and mixed financing: Universal MediShield Life coverage, combined with MediSave, MediFund, and private Integrated Shield Plans, creates a distinctive financing environment. Affordability, subsidy, and access research must reflect both public subsidy frameworks and private payer dynamics — making payer perception and willingness-to-pay research a critical component of Singapore market access strategy.
    • Cluster structure and APAC hub role: Singapore's public healthcare is organised into three regional clusters — SingHealth, NUHS, and NHG — each with distinct hospitals, prescribing patterns, and formulary decision-making. As an APAC hub, Singapore is often the anchor market for multi-country Southeast Asia research, requiring careful segmentation and consistent cross-market design.

    Singapore Payer Environment and ACE: What Market Researchers Must Know

    HSA and ACE

    HSA regulates therapeutic product registration and post-market surveillance. ACE conducts health technology assessments that inform MOH subsidy decisions. Market access research must align evidence to ACE cost-effectiveness methodology and MOH subsidy listing criteria.

    MOH Drug Subsidy

    The Ministry of Health (MOH) administers drug subsidy through the Standard Drug List (SDL) and Medication Assistance Fund (MAF). Listing decisions, informed by ACE HTAs, determine patient access and require dedicated payer and policy research.

    MediShield Life and Private Payers

    MediShield Life provides universal basic coverage to all residents, complemented by MediSave, MediFund, and private Integrated Shield Plans. Payer research must account for both public subsidy frameworks and private insurer perspectives.

    How to Evaluate a Market Research Partner for Singapore

    Selecting the right Singapore market research partner requires criteria beyond standard RFP evaluation. Singapore's cluster structure, ACE evidence requirements, PDPA compliance standards, and APAC regional research needs demand specific capabilities.

    PDPA and research ethics compliance

    Capability to design and execute HCP and patient research under Singapore research ethics standards and the Personal Data Protection Act (PDPA), with appropriate institutional review documentation.

    Public cluster HCP network (SingHealth, NUHS, NHG)

    Verified access to physicians and KOLs across Singapore’s three public healthcare clusters — SingHealth, NUHS, and NHG — as well as leading private hospitals.

    Payer research (MOH drug subsidy, SDL, MAF)

    Ability to conduct in-depth interviews with stakeholders involved in MOH drug subsidy decisions, Standard Drug List and Medication Assistance Fund listing, and hospital formulary decision-making.

    HSA and ACE evidence alignment

    Understanding of HSA regulatory processes and ACE health technology assessment methodology, and ability to design primary research evidence aligned to cost-effectiveness and subsidy listing requirements.

    HEOR and cost-effectiveness evidence generation

    Capability to generate primary willingness-to-pay data, budget impact inputs, and HEOR evidence aligned to ACE and MOH review standards.

    APAC regional research capability

    Ability to use Singapore as a hub for multi-market Southeast Asia and APAC research, with consistent instruments and methodology for cross-market benchmarking.

    7 Top Market Research Companies in Singapore (2026)

    The following profiles cover firms with demonstrated market research capability in Singapore. Each is assessed by use case and market positioning.

    1

    BioNixus

    Est. 2012HQ: Singapore (APAC) · UK (London)

    BioNixus is a specialist pharmaceutical and healthcare market research company serving Singapore-based and APAC-regional pharmaceutical, biotech, and medtech clients with HSA- and ACE-aligned primary research. Known for deep payer intelligence across MOH drug subsidy mechanisms (Standard Drug List and Medication Assistance Fund) and the ACE health technology assessment process, with verified HCP recruitment across the SingHealth, NUHS, and NHG public healthcare clusters and leading private hospitals.

    Best for

    • HSA- and ACE-aligned HCP surveys and KOL mapping
    • MOH drug subsidy and ACE HTA payer research
    • Market access evidence generation across public and private healthcare
    2

    IQVIA Singapore

    Est. 1982 (as IMS Health)HQ: Singapore

    IQVIA's Singapore operations provide prescription data analytics, real-world evidence, and secondary pharmaceutical intelligence across Singapore and the wider APAC region. Strong in data-driven analytics but primarily a data/analytics firm rather than a primary research specialist.

    Best for

    • Singapore and APAC prescription analytics
    • Real-world evidence and health outcomes
    • Secondary pharmaceutical intelligence
    3

    Ipsos Singapore

    Est. 1975 (Ipsos founded)HQ: Singapore

    Ipsos Singapore is the Singapore arm of the global Ipsos group, providing healthcare, patient, consumer, and brand tracking research across Singapore and Southeast Asia. Broad panel reach with generalist research capabilities spanning HCP surveys and patient studies.

    Best for

    • HCP quantitative research panels
    • Patient and consumer health research
    • Brand tracking and public health research
    4

    Kantar

    Est. 1992HQ: Singapore (APAC hub)

    Kantar is a global insights and consulting group with a significant APAC presence headquartered in Singapore. Known for brand tracking and equity studies with healthcare research capability, operating as a broad generalist agency rather than a pharmaceutical primary research specialist.

    Best for

    • Brand tracking and equity research
    • Healthcare and consumer research
    • Cross-market APAC research design
    5

    Milieu Insight

    Est. 2017HQ: Singapore

    Milieu Insight is a Singapore-headquartered consumer research and data platform with proprietary online panels across Southeast Asia. Strong in technology-enabled consumer data collection rather than specialist pharmaceutical or payer research.

    Best for

    • Singapore-headquartered consumer research platform
    • Online survey and panel data collection
    • Southeast Asia consumer insights
    6

    Blackbox Research

    Est. 2006HQ: Singapore

    Blackbox Research is a Singapore-based market research and public opinion firm known for sentiment tracking, social research, and brand studies. Primarily focused on consumer, public sector, and communications research rather than pharmaceutical market access.

    Best for

    • Singapore-based market and opinion research
    • Public sentiment and social research
    • Brand and communications research
    7

    Rakuten Insight

    Est. 2004HQ: Singapore (APAC operations)

    Rakuten Insight operates large online research panels across Singapore and the APAC region, supporting quantitative data collection and cross-market recruitment. Primarily a panel and data collection provider rather than a full-service pharmaceutical MR agency.

    Best for

    • APAC online research panels
    • Quantitative data collection at scale
    • Cross-market panel recruitment

    KOL Mapping and Payer Research in Singapore

    Singapore KOL mapping requires tracking influence across the three public healthcare clusters and leading private hospitals. SingHealth institutions (Singapore General Hospital, National Cancer Centre Singapore, National Heart Centre Singapore) hold strong guideline and publication influence in oncology, cardiovascular, and specialty areas; NUHS (National University Hospital, National University Cancer Institute Singapore) combines academic prominence with large trial enrolment volumes; NHG institutions (Tan Tock Seng Hospital, Khoo Teck Puat Hospital) lead in population health and community care influence. Effective Singapore KOL mapping segments influence by cluster, institution, therapy area, and prescribing volume.

    Singapore payer research requires access to MOH drug subsidy and ACE HTA stakeholders, and hospital formulary decision-makers — the most commercially important respondents in Singapore pharmaceutical research. Payer interviews cover subsidy listing preferences, ACE evidence thresholds, prior approval criteria, cost-effectiveness benchmarks, and SDL/MAF listing dynamics. BioNixus conducts public payer, policy, and private insurer interviews as dedicated payer research programs.

    BioNixus conducts KOL mapping and payer research across Singapore in oncology, cardiovascular, immunology, rare disease, metabolic, and other specialty areas. See our Singapore pharmaceutical market research guide and top healthcare market research companies in Singapore for details.

    Methodology & Selection Criteria

    This guide profiles firms with demonstrated market research operations in Singapore as of 2026. Selection criteria: (1) active Singapore operations with verified research capability, (2) relevance to healthcare, pharmaceutical, or consumer buyers in Singapore, (3) established track record in Singapore market research. Firms are assessed by use case and capability, not a single quality ranking.

    This guide is maintained by the BioNixus research team. BioNixus is included and is transparent about its participation. For corrections or updates, contact our team.

    Frequently Asked Questions

    Who are the top market research companies in Singapore in 2026?

    Leading market research companies in Singapore in 2026 include BioNixus, IQVIA Singapore, Ipsos Singapore, Kantar, Milieu Insight, Blackbox Research, and Rakuten Insight. BioNixus ranks first for pharmaceutical and healthcare research, with HSA- and ACE-aligned primary research, verified HCP recruitment across the SingHealth, NUHS, and NHG public healthcare clusters, and deep payer intelligence across MOH drug subsidy mechanisms and the ACE health technology assessment process.

    What is pharmaceutical market research in Singapore?

    Pharmaceutical market research in Singapore encompasses primary and secondary research designed to support commercial, market access, and regulatory decisions in the Singapore healthcare system. This includes HCP attitude-and-usage surveys, KOL mapping across the SingHealth, NUHS, and NHG clusters, payer research aligned to MOH drug subsidy decisions and the Agency for Care Effectiveness (ACE) health technology assessment process, and health economics research. As an APAC regional hub, Singapore is often used as a launch and headquarters market for pharmaceutical companies operating across Southeast Asia, making it a strategically important market for regional research design.

    How does HSA and ACE affect pharmaceutical market research in Singapore?

    The Health Sciences Authority (HSA) is Singapore's regulator for therapeutic products, responsible for drug registration and post-market surveillance. The Agency for Care Effectiveness (ACE), under the Ministry of Health (MOH), conducts health technology assessments (HTAs) that inform drug subsidy and listing decisions on the Standard Drug List (SDL) and Medication Assistance Fund (MAF). For market researchers, HSA and ACE create specific research requirements: cost-effectiveness and budget impact evidence aligned to ACE methodology, payer perception research among MOH and ACE decision-makers, and pricing and subsidy sensitivity studies that account for Singapore's drug subsidy framework.

    What payer research does BioNixus conduct in Singapore?

    BioNixus conducts payer research across Singapore, including in-depth interviews and advisory research with stakeholders involved in MOH drug subsidy decisions, ACE health technology assessment, and Standard Drug List (SDL) and Medication Assistance Fund (MAF) listing. BioNixus also covers MediShield Life and Integrated Shield Plan coverage perspectives, hospital pharmacy and formulary decision-makers across the SingHealth, NUHS, and NHG clusters, and private payer dynamics. Payer research is designed around the specific decision criteria applied in Singapore drug subsidy and HTA evaluation.

    How much does market research cost in Singapore?

    Custom market research engagements in Singapore typically range from SGD $40,000 to SGD $150,000 per project depending on methodology, respondent type, and research complexity. Pharmaceutical studies with specialist HCP recruitment across the public healthcare clusters, KOL mapping, or payer depth interviews cost more than standard consumer surveys. Multi-market APAC programs that use Singapore as a regional hub add scope versus single-market designs. Costs vary with sample size, fieldwork mode, and the seniority of the HCP and payer respondents required.

    Is BioNixus aligned with Singapore research ethics and data protection standards?

    Yes. BioNixus designs and executes Singapore HCP and patient research in accordance with applicable research ethics and data protection requirements, including the Personal Data Protection Act (PDPA) and institutional review processes for studies involving HCPs and patients across the SingHealth, NUHS, and NHG clusters and private healthcare providers. Studies are designed with appropriate consent procedures and data privacy protections aligned to Singapore standards.

    What is the role of MOH and MediShield Life in Singapore pharmaceutical strategy?

    The Ministry of Health (MOH) oversees Singapore's healthcare system, including drug subsidy frameworks such as the Standard Drug List (SDL) and Medication Assistance Fund (MAF), informed by ACE health technology assessments. MediShield Life is Singapore's universal basic health insurance scheme providing lifelong coverage to all residents, complemented by MediSave, MediFund, and Integrated Shield Plans. For pharmaceutical market researchers, MOH subsidy decisions and the MediShield Life framework create specific research requirements: cost-effectiveness evidence aligned to ACE thresholds, payer and policy perception research, and affordability and access studies reflecting Singapore's mixed financing model.

    Can Singapore market research connect to global and APAC benchmarking?

    Yes. BioNixus connects Singapore research to global and APAC benchmarking programs using consistent instruments and methodology across markets. Singapore HCP and payer studies can be benchmarked against US, UK, EU5, and other APAC cohorts — essential for global pharmaceutical clients making simultaneous market access decisions. As an APAC regional hub, Singapore is frequently the anchor market for multi-country Southeast Asia research, making consistent cross-market research design a practical necessity for regional and global pharma clients.

    Plan Market Research in Singapore

    BioNixus delivers HSA- and ACE-aligned pharmaceutical and healthcare market research across Singapore — HCP surveys across the SingHealth, NUHS, and NHG clusters, KOL mapping, MOH drug subsidy and ACE HTA payer research, and HEOR evidence generation. Global standards. In-market APAC execution.

    Request a proposal